| Lessons in PROTAC design from selective degradation with a promiscuous warhead DP Bondeson, BE Smith, GM Burslem, AD Buhimschi, J Hines, ... Cell chemical biology 25 (1), 78-87. e5, 2018 | 773 | 2018 |
| The advantages of targeted protein degradation over inhibition: an RTK case study GM Burslem, BE Smith, AC Lai, S Jaime-Figueroa, DC McQuaid, ... Cell chemical biology 25 (1), 67-77. e3, 2018 | 595 | 2018 |
| BiP maintains the permeability barrier of the ER membrane by sealing the lumenal end of the translocon pore before and early in translocation BD Hamman, LM Hendershot, AE Johnson Cell 92 (6), 747-758, 1998 | 569 | 1998 |
| Differential PROTAC substrate specificity dictated by orientation of recruited E3 ligase BE Smith, SL Wang, S Jaime-Figueroa, A Harbin, J Wang, BD Hamman, ... Nature communications 10 (1), 131, 2019 | 453 | 2019 |
| The aqueous pore through the translocon has a diameter of 40–60 Å during cotranslational protein translocation at the ER membrane BD Hamman, JC Chen, EE Johnson, AE Johnson Cell 89 (4), 535-544, 1997 | 386 | 1997 |
| Identification of a membrane-spanning domain of the thiol-activated pore-forming toxin Clostridium perfringens perfringolysin O: an α-helical to β-sheet transition identified … LA Shepard, AP Heuck, BD Hamman, J Rossjohn, MW Parker, KR Ryan, ... Biochemistry 37 (41), 14563-14574, 1998 | 374 | 1998 |
| Identification and characterization of Von Hippel-Lindau-recruiting proteolysis targeting chimeras (PROTACs) of TANK-binding kinase 1 AP Crew, K Raina, H Dong, Y Qian, J Wang, D Vigil, YV Serebrenik, ... Journal of medicinal chemistry 61 (2), 583-598, 2018 | 267 | 2018 |
| A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases SM Rodems, BD Hamman, C Lin, J Zhao, S Shah, D Heidary, L Makings, ... Assay and drug development technologies 1 (1), 9-19, 2002 | 209 | 2002 |
| Miniaturized FRET assays and microfluidics: key components for ultra-high-throughput screening L Mere, T Bennett, P Coassin, P England, B Hamman, T Rink, ... Drug Discovery Today 4 (8), 363-369, 1999 | 165 | 1999 |
| Inhibition of AAK1 kinase as a novel therapeutic approach to treat neuropathic pain W Kostich, BD Hamman, YW Li, S Naidu, K Dandapani, J Feng, A Easton, ... Journal of Pharmacology and Experimental Therapeutics 358 (3), 371-386, 2016 | 101 | 2016 |
| Optical probes and assays BA Pollok, BD Hamman, SM Rodems, LR Makings US Patent 6,410,255, 2002 | 94 | 2002 |
| Novel class of LIM-kinase 2 inhibitors for the treatment of ocular hypertension and associated glaucoma BA Harrison, NA Whitlock, MV Voronkov, ZY Almstead, K Gu, R Mabon, ... Journal of medicinal chemistry 52 (21), 6515-6518, 2009 | 90 | 2009 |
| Location and domain structure of Escherichia coli ribosomal protein L7/L12: site specific cysteine cross-linking and attachment of fluorescent probes RR Traut, D Dey, DE Bochkariov, AV Oleinikov, GG Jokhadze, B Hamman, ... Biochemistry and cell biology 73 (11-12), 949-958, 1995 | 76 | 1995 |
| Tetramethylrhodamine Dimer Formation as a Spectroscopic Probe of the Conformation of Escherichia coli Ribosomal Protein L7/L12 Dimers (∗) BD Hamman, AV Oleinikov, GG Jokhadze, DE Bochkariov, RR Traut, ... Journal of Biological Chemistry 271 (13), 7568-7573, 1996 | 74 | 1996 |
| Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers J Cantley, X Ye, E Rousseau, T Januario, BD Hamman, CM Rose, ... Nature Communications 13 (1), 6814, 2022 | 65 | 2022 |
| Protein-protein interaction inducing technology J Wang, AP Crew, H Dong, T Neklesa, B Hamman US Patent App. 15/477,966, 2017 | 63 | 2017 |
| Discovery of a type III inhibitor of LIM kinase 2 that binds in a DFG-out conformation NC Goodwin, G Cianchetta, HA Burgoon, J Healy, R Mabon, ED Strobel, ... ACS medicinal chemistry letters 6 (1), 53-57, 2015 | 62 | 2015 |
| Profound obesity secondary to hyperphagia in mice lacking kinase suppressor of ras 2 JP Revelli, D Smith, J Allen, S Jeter‐Jones, MK Shadoan, U Desai, ... Obesity 19 (5), 1010-1018, 2011 | 61 | 2011 |
| Dimer/monomer equilibrium and domain separations of Escherichia coli ribosomal protein L7/L12 BD Hamman, AV Oleinikov, GG Jokhadze, RR Traut, DM Jameson Biochemistry 35 (51), 16680-16686, 1996 | 61 | 1996 |
| Discovery and Development of LX7101, a Dual LIM-Kinase and ROCK Inhibitor for the Treatment of Glaucoma BA Harrison, ZY Almstead, H Burgoon, M Gardyan, NC Goodwin, J Healy, ... ACS medicinal chemistry letters 6 (1), 84-88, 2015 | 56 | 2015 |
